Deaths from cardiovascular disease involving anticoagulants: a systematic synthesis of coroners' case reports to prevent future deaths

Ali Anis (0000-0003-4680-4541) medical student[1];
Carl Heneghan (0000-0002-1009-1992), DPhil, Director[2] and Co-Director[3];
Jeffrey K. Aronson (0000-0003-1139-655X), DPhil, Clinical Pharmacologist[2];
Nicholas J. DeVito (0000-0001-8286-1995), MPH, doctoral researcher[4];
Georgia C. Richards (0000-0003-0244-5620), BSc (Hons I), doctoral researcher[2] and Research Fellow[3].*

[1]Oxford University Medical School, John Radcliffe Hospital, Headington, University of Oxford, Oxford, OX3 9DU, UK.

[2]Centre for Evidence-Based Medicine, Nuffield Department of Primary Care Health Sciences, University of Oxford, Radcliffe Observatory Quarter, Woodstock Road, Oxford, OX2 6GG, UK.

[3]Global Centre on Healthcare and Urbanisation, Kellogg College, University of Oxford, 60-62 Banbury Road, Oxford, OX2 6PN, UK.

[4]EBM Datalab, Nuffield Department of Primary Care Health Sciences, University of Oxford, Radcliffe Observatory Quarter, Woodstock Road, Oxford, OX2 6GG, UK.

*Corresponding author: Georgia C. Richards; Global Centre on Healthcare and Urbanisation, Kellogg College, University of Oxford, 60-62 Banbury Road, Oxford, OX2 6PN, UK; email: georgia.richards@kellogg.ox.ac.uk; phone: +44 7902 410 774

Word count: 2353

Abstract

Background: The global burden of cardiovascular disease (CVD) is forecast to increase, and anticoagulants will remain important medicines for its management. Coroners' Prevention of Future Death reports (PFDs) provide valuable insights that may enable safer and more effective use of these agents.

Objective: To identify CVD-related PFD reports highlighting the use or lack of anticoagulants as having caused or contributed to deaths.

Methods: We conducted a retrospective observational study of coronial case reports in England and Wales between 2013 and 2019. We screened 3037 PFDs for inclusion and used content analysis to assess concerns raised by coroners and who responded to them.

Results: We identified 113 CVD-related PFDs (113 deaths) involving anticoagulants. Warfarin (36%), enoxaparin (11%), and rivaroxaban (11%) were the most common anticoagulants reported. In 14 cases, the coroner mentioned that the administration of an anticoagulant may have prevented the death. Concerns most frequently raised by coroners included poor systems (31%), poor communication (25%), and failures to keep accurate medical records (25%). These concerns were most often directed to NHS trusts (29%), hospitals (10%), and general practices (8%), but had national importance. Nearly two-thirds (60%) of PFDs had not received responses from such organisations, which are mandatory under regulation 28 of the Coroners' (Investigations) Regulations 2013.

Conclusions: We created a tool (https://preventabledeathstracker.net/) that bring together coroner reports to identify important lessons related to preventable deaths. Here we examined instances of premature deaths from CVD involving anticoagulants. National organisations, healthcare professionals, and prescribers should take actions to address these concerns, to improve the use of anticoagulants in patients with CVD.

Keywords: cardiovascular diseases, anticoagulants, inappropriate prescribing, medication errors, premature mortality, coroners and medical examiners

Key questions

What is already known?

A previous assessment of 500 PFDs identified anticoagulants as the class of drugs most often involved in fatal medication errors.

What does this study add?

We used innovative methods to automatically collect all available PFDs, in order to identify deaths from cardiovascular disease when the use of or lack of anticoagulants caused or contributed to the death. We found that communication, following protocols, education and training, access to resources, and safety issues were raised as concerns by coroners. Despite having national relevance, most CVD-anticoagulant PFDs were sent locally to NHS Trusts, hospitals, and general practices.

How might this impact on clinical practice?

Local dissemination and poor responses to PFDs limits the ability of lessons to be learnt and actions to be implemented to reduce harms and prevent premature deaths from cardiovascular disease involving anticoagulants. The concerns highlighted by coroners should be addressed by national organisations to improve safety and management of patients with cardiovascular disease.

Introduction

Cardiovascular disease (CVD) is the leading cause of mortality worldwide [1,2]. In 2019, 18.6 million deaths (33% of all deaths) were due to CVD [3], with a projection of 24 million annual deaths by 2030 [4]. In England and Wales, CVD was responsible for almost a quarter of all deaths in 2019 [5,6]. Premature mortality from CVD in England has also been attributed to greater socioeconomic inequalities in people under 75 years of age [7].

In patients at high risk of strokes, heart attacks, deep vein thrombosis, or pulmonary embolism, anticoagulation is one possible prophylactic intervention [8]. Anticoagulants target different points of the coagulation cascade, helping to prevent blood clot formation and the adverse effects of excessive clotting. Three main types of anticoagulants are outlined in NICE guidelines: low molecular weight heparin (e.g. enoxaparin), vitamin K antagonists (e.g. warfarin), and direct-acting oral anticoagulants (DOACs; e.g. rivaroxaban). The effectiveness of anticoagulants for cardiovascular disease is well established. For example, adjusted-dose warfarin reduced stroke by 62% (95% CI: 48% to 72%) in patients with atrial fibrillation [9]. However, the narrow therapeutic index and frequent laboratory monitoring needed with warfarin administration have led to the development of DOACs [10]. Bleeding associated with warfarin therapy is among the top three adverse drug reactions that cause hospital admissions in England [11].

In English primary care, prescribing of anticoagulants increased from 15 million doses to 33 million between January 2014 and August 2019 [12]. Coroners' reports, previously named Rule 43 reports and now called Prevention of Future Death reports (PFDs), are mandated under paragraph 7 of Schedule 5 of the Coroners and Justice Act 2009, when the coroner believes that action is necessary to prevent a death [13]. PFDs are sent to specific individuals or organisations, who, under regulation 28 and 29 of the Coroners (Investigations) Regulations 2013, have a duty to respond within 56 days of the date of report [14]. Previous analysis of coroners' reports has shown that anticoagulants were the drugs most commonly reported to have been involved in fatal medication errors in England and Wales [15]. But that research examined only a proportion (n=500) of all published coroners' reports. Building on previous research, we aimed to assess all available PFDs on deaths in individuals with CVD, in whom the use or lack of use of anticoagulants caused or contributed to the death. We sought to discover: 1) what concerns were highlighted by coroners; 2) to which individuals or

organizations PFDs were addressed; 3) whether responses were made by the individuals or organizations to whom the PFDs were sent.

Methods

We designed a retrospective observational study and preregistered our study protocol on an open repository [16]. We used the STROBE reporting guideline to write our manuscript.

Data collection

PFDs are openly available on the Courts and Tribunals Judiciary website [17]. We used web scraping to automatically collect PFDs, and from the output created the Preventable Deaths Database and the Preventable Deaths Tracker: https://preventabledeathstracker.net/ [18]. The code to create the scraper is openly available on GitHub [19] and has been previously described [20]. The Preventable Deaths Database contains: the case reference number; the date of the report; the name of the deceased; the coroner's name; the coroner's jurisdiction; the category of death (defined by the Chief Coroners' office); to whom the report was sent; and the URL to the Judiciary website. For population data on deaths from CVD, we used the most recent (2001-2019) dataset of deaths registered in England and Wales, released by the Office for National Statistics in 2020 (ONS) [5].

Eligibility of cases

We examined all cases (n=3037) in the Preventable Deaths Database from July 2013 (the first date on which they were uploaded to the Judiciary website) to December 2019. We screened the cases independently in duplicate (AA & GCR) to determine whether CVD caused or contributed to the death using a pre-defined algorithm (Supplementary Figure 1). We used Chapter IX (Diseases of the Circulatory System) of the International Statistical Classification of Diseases and Related Health Problems 10th Revision (ICD-10) to align with the ONS classifications of death. When the deceased suffered from a single condition listed under chapter IX that could not be unequivocally attributed to external causes, the case was included. We then screened cases for whether an anticoagulant(s) caused or contributed to the death or where the coroner suggested that had an anticoagulant been given, it would have prevented the death. We defined anticoagulants as agents targeting different points of the coagulation pathway to prevent clot formation. Discrepancies were resolved by consensus discussion (AA, GCR, & JKA).

Data extraction

For included cases, one study author (AA) manually extracted the following variables into a predesigned Google Sheet: the individuals or organizations to whom reports were sent, who responded, the due date of response and the date received; date of death; the dates on which the inquest started and ended; age; sex; setting or location of death; medical cause(s) of death; the coroner's conclusion(s) of the inquest; relevant medical, mental health, and social history; whether any substance(s) were implicated in the death and the type of substance(s); coroner's concern(s) and actions proposed by the coroner.

Data analysis

To determine the annual deaths from CVD in England and Wales, we filtered the ONS data [5] for deaths caused by conditions listed under chapter IX of ICD-10 (ICD-10 codes: I00-I99). We summed the number of reports written each year and compared the totals with ONS mortality data for CVD. We used descriptive statistics to report the quantitative findings and performed content analysis [21] to classify the concerns and actions raised by coroners with categories derived inductively. We calculated a response rate for each organisation as the proportion of reports to which a response was submitted over the total number received. Responses were further classified as either on-time (delivered within 56 days), late (submitted after 56 days), or overdue (when no response was found on the Judiciary website). A response rate of 100% means that individual or organisation adhered to regulation 28 of the Coroners' (Investigations) Regulations 2013 and responded to all PFDs issued by coroners. We used Python v3.7 in Jupyter Notebooks with pandas, seaborn, and matplotlib libraries to analyse the data and create figures. The data, statistical code, and study materials are openly available via the Open Science Frame [22] and GitHub [23].

Results

In 659 cases (22% of all PFDs) CVD caused or contributed to the death (Figure 1). Of the CVD-related PFDs, 17% (n=113) involved or mentioned the use or lack of an anticoagulant. Over the seven-year study period, there was a median of 16 (IQR: 15-17) CVD-related anticoagulant PFDs each year (Supplementary Table 1).



Figure 1: Flow diagram showing the numbers of Prevent Future Death reports (PFDs) included and excluded from the Preventable Deaths Database using the eligibility criteria for this study

In 99 cases, an anticoagulant(s) caused or contributed to the death. Warfarin (36%) was the most common anticoagulant specified, followed by enoxaparin (11%) and rivaroxaban (11%) (Figure 2). In 14 cases, the coroner mentioned that the administration of an anticoagulant might have prevented the death (Figure 2). There were equal proportions of males (n=56) and females (n=57) in the 113 cases. The median age of the deceased were 76 years (IQR: 61-84 years; n=77).



Figure 2: Anticoagulants reported in cardiovascular disease-related Prevent Future Death reports (PFDs). *in these PFDs, the coroner suggested that if an anticoagulant had been used the death might have been prevented

Seventy-five coroners across 36 jurisdictions wrote 113 PFDs. Coroners in the North West (25%) and South East (19%) of England wrote the most, whereas those in the East (2%) and North East (3%) of England wrote very few (Table 1).

Table 1: Jurisdictions of coroners who issued the 113 Prevent Future Death reports involving an anticoagulant and cardiovascular disease

Region	No. of cases (%)
North West England	**28 (25)**
Greater Manchester	20 (18)
Blackpool & Fylde	4 (4)
Blackburn, Hyndburn & Ribble Valley	3 (3)
Cumbria	1 (1)
South East England	**21 (19)**
Surrey	4 (4)

Kent	3 (3)
Milton Keynes	3 (3)
Portsmouth & South East Hampshire	3 (3)
West Sussex	3 (3)
Buckinghamshire	2 (2)
Berkshire	1 (1)
Isle of Wight	1 (1)
Oxfordshire	1 (1)
Wales	**15 (13)**
Powys, Bridgend & Glamorgan Valleys	6 (5)
North Wales	2 (2)
South Wales	2 (2)
Swansea	2 (2)
Cardiff & Vale of Glamorgan	1 (1)
Carmarthenshire & Pembrokeshire	1 (1)
Gwent	1 (1)
London	**10 (9)**
West Midlands	**13 (12)**
Black Country	5 (4)
Birmingham & Solihull	4 (4)
Coventry	1 (1)
Shropshire, Telford & Wrekin	1 (1)
South Staffordshire	1 (1)
Worcestershire	1 (1)
Yorkshire and The Humber	**8 (7)**
South Yorkshire	5 (4)
West Yorkshire	3 (3)
East Midlands	**7 (6)**
Leicestershire	4 (4)
Nottinghamshire	3 (3)
South West England	**6 (5)**
Plymouth, Torbay & South Devon	4 (4)
Avon	1 (1)
Gloucestershire	1 (1)
North East England	**3 (3)**
Sunderland	3 (3)
East of England	**2 (2)**

Cambridgeshire	1 (1)
Norfolk	1 (1)

We identified 335 individual concerns raised by coroners in the 113 cases. Using content analysis, we categorised these concerns into 51 groups and five higher-order themes, including communication, failure to follow protocols, education and training, resources, and safety (Table 2). The most common concerns were poor systems (31%), poor communication (25%), failure to keep accurate medical records (25%), and failures or delays in having appropriate assessments done (17%). Concerns most frequently belonged to the theme of following protocols (36%), followed by communication (22%), and safety issues (21%).

Table 2: Concerns raised by coroners, grouped by five higher-order themes, and how often they were reported

Theme (% of concerns)	Concern	No. of cases (%)
Failure to follow protocols (36%)	Failure/delay in appropriate assessments	19 (17)
	Failure to monitor treatment	15 (13)
	Omission of necessary treatment	13 (12)
	Delayed treatment	12 (11)
	Failure to review medicines	11 (10)
	Failure to take a history or see the patient	10 (9)
	Failure/delay in performing necessary scans	8 (7)
	Failure to triage patients appropriately	7 (6)
	Failure to follow recommended practices	6 (5)
	Failure to follow a protocol	6 (5)
	Failure to review medical records	4 (4)
	Failure to implement national guidelines	3 (3)
	Administration of drug in error	1 (1)
	Failure to arrange supervision	1 (1)
	Inability to care for both a patient's physical and mental health	1 (1)
	Management of medication for care home residents	1 (1)
	Medication administered despite known allergy	1 (1)
Communication (22%)	Poor communication	28 (25)
	Failure to keep accurate medical records	28 (25)
	Failure to escalate deterioration in patient to the relevant medical professionals	5 (4)
	Failure to seek specialist advice when indicated	4 (4)
	Failure to follow the advice of a senior clinician	2 (2)
	Failure to warn of the consequences of not taking medication	2 (2)

	Failure to inform the patient about a medical procedure and aftercare	2 (2)
	Failure to warn of adverse drug reactions	1 (1)
	Failure to obtain informed consent	1 (1)
Safety (21%)	Poor systems	35 (31)
	Discharge process	16 (14)
	Non-robust investigation following the death	15 (13)
	Safety of facilities	2 (2)
	Nature of inspections of care homes	1 (1)
	Failure to address measures identified in risk assessment	1 (1)
	Failure to make a reasonable effort to ensure patient adherence	1 (1)
Education and training (14%)	Inadequate training	12 (11)
	Inappropriate dosage for the patient	9 (8)
	Failure to appreciate the risk (of giving/not giving a drug)	6 (5)
	Lack of clinical knowledge	5 (4)
	Poor clinical decision-making	5 (4)
	Poor awareness of symptoms	4 (4)
	Poor awareness of rare ADRs	2 (2)
	Poor awareness of rare complications of medical procedures	1 (1)
	Failure of training	1 (1)
	Drug awareness	1 (1)
	Poor awareness of drug-drug interactions	1 (1)
	Wrong method of administration	1 (1)
Resources (7%)	Absence of national guidelines	10 (9)
	Under staffing	7 (6)
	Shortage/lack of availability of appropriate medical equipment	3 (3)
	Hospital opening times/availability	2 (2)
	Unavailable drug	1 (1)
	Inability to deliver care	1 (1)

In 82% of CVD-related PFDs involving anticoagulants, coroners stated that "action should be taken" (Supplementary Table 2). When coroners suggested further actions, we grouped their actions into 28 categories. Ensuring effective communication (3%), introducing new policies and protocols (2%), and reviewing the handling of prescriptions (2%) were the most common actions proposed (Supplementary Table 2).

For the 113 CVD-related PFDs involving anticoagulants, coroners sent 181 reports to individuals or organisations, collated into 37 groups (Table 3). NHS Trusts (29%), hospitals (10%), and general practices (8%) were addressed most frequently. By statute addressees must respond to the coroner within 56-days, but only 29% responded on time; 11%

responded late and 60% were overdue. Medical societies (0%) and royal colleges (0%) had the lowest response rates, while NHS entities had the highest, albeit with a collective response rate of 51%. Ranking recipients by response rate and response time, NHS 111, NHS Wales, and CCGs performed best (Supplement Table 3).

Table 3: Recipients of coroners Prevent Future Death reports (PFDs) and their response rates to reports

Addressee	No. of reports received	No. of responses	Response rate (%)	Classification of responses		
				% On time	% Late	% Overdue
NHS entities	**118**	**60**	**51**	**38**	**13**	**49**
CCGs	3	3	100	67	33	0
NHS 111	1	1	100	100	0	0
NHS Wales	1	1	100	100	0	0
Ambulance services	7	5	71	57	14	29
NHS Trusts	53	32	60	45	15	40
NHS England	4	2	50	50	0	50
hospitals	19	7	37	26	11	63
General practices	14	5	36	29	7	64
Local Health Boards	3	1	33	0	33	67
University Health Boards	10	3	30	20	10	70
Mental Health Trusts	2	0	0	0	0	100
NHS Pathways	1	0	0	0	0	100
Government	**17**	**5**	**29**	**18**	**12**	**71**
DHSC	7	3	43	14	29	57
Local authorities	3	1	33	33	0	67
Welsh Government	7	1	14	14	0	86
Professional bodies	**21**	**4**	**19**	**10**	**10**	**81**
CQC	6	2	33	17	17	67
NICE	8	2	25	13	13	75
GMC	2	0	0	0	0	100
BMA	1	0	0	0	0	100
GDC	1	0	0	0	0	100
MHRA	1	0	0	0	0	100
AACE	1	0	0	0	0	100

The Renal Association	1	0	0	0	0	100
Others	**18**	**3**	**17**	**11**	**6**	**83**
Police	1	1	100	0	100	0
Private companies	4	1	25	25	0	75
Care homes	9	1	11	11	0	89
Carewatch	1	0	0	0	0	100
Highway maintenance	1	0	0	0	0	100
Housing Associations	1	0	0	0	0	100
Local Charities	1	0	0	0	0	100
Medical societies	**4**	**0**	**0**	**0**	**0**	**100**
BCS	1	0	0	0	0	100
BRS	1	0	0	0	0	100
ICS	1	0	0	0	0	100
RPS	1	0	0	0	0	100
Medical royal colleges	**3**	**0**	**0**	**0**	**0**	**100**
RCGP	1	0	0	0	0	100
RCOG	1	0	0	0	0	100
RCP	1	0	0	0	0	100
Total	181	72	40	29	11	60

AACE: Association of Ambulance Chief Executives; BCS: British Cardiovascular Society; BMA: British Medical Association; BRS: British Renal Society; CQC: Care Quality Commission; DHSC: Department of Health and Social Care; GDC: General Dental Council; GMC: General Medical Council; ICS: Intensive Care Society; MHRA: Medicines and Healthcare products Regulatory Agency; NICE: The National Institute for Health and Care Excellence; NHS: National Health Service; RCGP: Royal College of General Practitioners; RCOG: Royal College of Obstetricians and Gynaecologists; RCP: Royal College of Physicians; RPS: Royal Pharmaceutical Society

Discussion

Summary

We identified 113 premature deaths from cardiovascular disease involving anticoagulants. In 88% of cases, the use of one anticoagulant or more resulted in death. In 12% of cases, death was attributed to the absence of anticoagulation. We found wide geographical variation in the issuing of PFDs and the type of information reported, with coroners in Greater Manchester writing the most. Coroners raised many concerns, which we categorised into five themes: failure to follow protocols, communication, safety issues, education and training, and the lack of adequate resources. Most of these concerns were addressed locally and under regulation 28, 109 individuals or organisations were overdue in their response to such concerns.

Strengths and limitations

We used a reproducible data-collection method to examine all available PFDs from inception to 2019, which provided an estimated 40-fold time saving [20], and reduced the potential for selection bias. However, the PFDs included in our study depend on the working practices of coroners and the Chief Coroner's Office in uploading PFDs and their responses to the website. The 113 PFDs cannot therefore represent all preventable deaths from CVD involving anticoagulants in England and Wales. There were also missing data; for example, 32% of PFDs did not report age and 16% did not specify the type of anticoagulant; this may be attributed to lack of PFD training provided to coroners.

Comparison with existing literature

Our study builds on prior research that evaluated smaller samples of coroners' reports [15,24–27]. Compared with previous studies [26,28], we did not identify a sex imbalance. However, we found that most PFDs were addressed locally, as shown by Ferner et al. [15], which means that valuable lessons were not widely disseminated and may be why we found that coroners repeatedly expressed similar concerns, in line with former research [25]. This questions whether PFDs are fulfilling their purpose. Similar to Fox and Jacobson [26], we found pronounced geographical variation in the issuing of PFDs and poor response rates. A review of the coronial system in England and Wales highlighted lack of accountability, leadership, and quality assurance [29]. Since there is no system in place for enforcing or auditing compliance with regulation 28 or assessing the quality of PFDs and the adequacy of responses and actions taken to prevent deaths, our findings show that the system has scope for improvement. Fortunately, the value of PFDs as a tool for improving clinical practice is being recognised, and efforts are underway to widely disseminate these lessons to healthcare professionals, policymakers, and the public [30–34].

Implications for research and clinical practice

Concerns raised by coroners provide lessons for prescribers and policymakers on the safety and proper use of therapies. During the COVID-19 pandemic, patients were switched from warfarin to other oral anticoagulants, given the need for less frequent blood testing [35]. Drugs such as andexanet alfa could prove critical in the outcome of patients with severe bleeding during treatment with apixaban or rivaroxaban. Since the coroner expressed concerns (Case: 2018-0032), NICE has drafted an appraisal for andexanet alfa [36], and its publication is expected on 12 May 2021 [37]. There has also been a phased launch of

andexanet alfa in UK hospitals [38]. However, it is unclear whether this was a direct result of the PFD, since no response from the MHRA was published on the Judiciary website.

When PFDs are addressed to the appropriate recipients at the national level, their actions can help prevent deaths. For example, a PFD was sent to NICE when the deceased suffered a fall while taking an anticoagulant without having the appropriate neuroimaging performed (Case: 2019-0106). The coroner's concerns were acknowledged in a NICE surveillance report [39] and resulted in updating of the NICE guideline on head injury, to emphasise that people taking DOACs should be investigated with the same care as those taking warfarin [40]. However, we also identified unaddressed concerns about national guideline; three-quarters of PFDs sent to NICE have no responses listed on the Judiciary website. Restarting warfarin after a head injury is particularly important, as delays could leave the patient at risk of a stroke, but resuming too soon may lead to haemorrhage. A retrospective review of the medical charts of 256 patients admitted to a trauma centre in West Texas between 2009 and 2012 showed that patients who resumed anticoagulant therapy at 7-10 days after the injury had the best prognosis [41]. PFDs can therefore be used to update guidance and inform future prospective cohort studies.

Our study provides a database and resource (https://preventabledeathstracker.net/) for future evaluations of PFDs. Further content analysis should be used to assess the 181 responses to the 113 PFDs, to assess the adequacy of actions taken or proposed to prevent deaths. Future research could use our open data to examine coroners' concerns in the 546 CVD-related PFDs not involving anticoagulants and their responses. In building the web scraper to collect PFDs, we found various inconsistencies and omissions on the Judiciary website, which should be addressed to improve the quality of the data. The missing data from PFDs we have highlighted reveal target areas for coronial training in the writing of PFDs.

Conclusions

PFDs provide valuable lessons when prescribing anticoagulants and managing patients with CVD. However, it is unclear whether actions are being taken to incorporate such lessons. To improve patient safety, PFDs should be widely disseminated.

Funding: No funding was obtained to undertake this study.

Ethical approval: As the case reports are publicly available on the Judiciary website, approval from an ethics committee was not required.

Contributions: AA proposed the topic for research, contributed to the protocol and devised the algorithm for the eligibility of cases, screened the database for eligible case reports, extracted and analysed the data, and wrote the first draft of the manuscript. GCR designed the study, wrote the protocol, sourced the data, contributed to the web scraper, provided data management, dual screened the database for eligible cases, analysed the data, provided primary supervisory support and substantiality contributed to subsequent manuscript drafts. JKA and CH reviewed the protocol and preliminary findings and provided supervisory support. NJD wrote the code and advised on the web scraper. All authors have full access to all the data in the study, read and approved the final manuscript, and accept responsibility to submit for publication.

Data availability: Study materials, protocol, data, and statistical code are openly available on the OSF (https://osf.io/qkfjp/) and GitHub (https://github.com/georgiarichards/CVD_anticoags).

Competing interests: AA has no competing interest to disclose. CH is a National Institute for Health Research (NIHR) Senior Investigator and has received expenses and fees for his media work, received expenses from the World Health Organisation (WHO), Food and Drug Administration (FDA), and holds grant funding from the NIHR School for Primary Care Research (SPCR), and the NIHR SPCR Evidence Synthesis Working Group [Project 380], the NIHR BRC Oxford and the WHO. On occasion, CH receives expenses for teaching EBM and is also paid for his GP work in NHS out of hours (contract with Oxford Health NHS Foundation Trust). CH is the Director of the CEBM. JKA has published articles and edited textbooks on adverse drug reactions and interactions and has often given medicolegal advice, including appearances as an expert witness in coroners' courts, dealing with the adverse effects of drugs. NJD has no conflicts related to the submitted work. Outside the submitted work, he declares a doctoral studentship from the Naji Foundation, grant funding from the Fetzer Franklin Memorial Fund, and employment on grants from the Laura and John Arnold Foundation, The Good Thinking Society, and the German Federal Ministry of Education and

Research (BMBF). GCR was financially supported by the NIHR SPCR, the Naji Foundation, and the Rotary Foundation to study for a Doctor of Philosophy (2017-2020) but no longer has any financial COIs. GCR is an Associate Editor of BMJ Evidence Based Medicine. The views expressed are those of the authors and not necessarily those of the NHS, the NIHR, or the Department of Health and Social Care.

References

1. Cardiovascular diseases (CVDs) [Internet]. who.int. 2017 [cited 2020 Dec 15]. Available from: https://www.who.int/news-room/fact-sheets/detail/cardiovascular-diseases-(cvds)
2. CVD risk assessment and management [Internet]. NICE. 2019 [cited 2021 Jan 18]. Available from: https://cks.nice.org.uk/topics/cvd-risk-assessment-management/
3. GBD Results Tool [Internet]. Global Health Data Exchange. 2020 [cited 2020 Dec 15]. Available from: http://ghdx.healthdata.org/gbd-results-tool
4. The Future of CVD [Internet]. who.int. [cited 2020 Dec 15]. Available from: https://www.who.int/cardiovascular_diseases/en/cvd_atlas_25_future.pdf?ua=1
5. Deaths registered in England and Wales – 21st century mortality [Internet]. Office for National Statistics. 2020 [cited 2020 Dec 15]. Available from: https://www.ons.gov.uk/peoplepopulationandcommunity/birthsdeathsandmarriages/deaths/datasets/the21stcenturymortalityfilesdeathsdataset
6. ICD-10 Version:2019 [Internet]. who.int. 2019 [cited 2020 Dec 15]. Available from: https://icd.who.int/browse10/2019/en#/IX
7. Lewer D, Jayatunga W, Aldridge RW, Edge C, Marmot M, Story A, et al. Articles Premature mortality attributable to socioeconomic inequality in England between 2003 and 2018: an observational study. Lancet Public Heal [Internet]. 2020 [cited 2021 Feb 13];5:e33–41. Available from: https://doi.org/10.1016/S2468-2667(19)30219-1
8. Anticoagulants, including direct-acting oral anticoagulants (DOACs) [Internet]. NICE. 2016 [cited 2021 Jan 18]. Available from: https://www.nice.org.uk/advice/ktt16/resources/anticoagulants-including-directacting-oral-anticoagulants-doacs-pdf-58757956094149

9. Hart RG, Benavente O, McBride R, Pearce LA. Antithrombotic therapy to prevent stroke in patients with atrial fibrillation: A meta-analysis. Ann Intern Med [Internet]. 1999 Oct 5 [cited 2021 Feb 3];131(7):492–501. Available from: https://doi.org/10.7326/0003-4819-131-7-199910050-00003

10. Harter K, Levine M, Henderson SO. Anticoagulation drug therapy: A review. West J Emerg Med [Internet]. 2015 [cited 2021 Jan 18];16(1):11–7. Available from: https://doi.org/10.5811/westjem.2014.12.22933

11. Pirmohamed M, James S, Meakin S, Green C, Scott AK, Walley TJ, et al. Adverse drug reactions as cause of admission to hospital: Prospective analysis of 18 820 patients. Br Med J [Internet]. 2004 Jul 3 [cited 2021 Feb 3];329(7456):15–9. Available from: https://doi.org/10.1136/bmj.329.7456.15

12. Ho KH, Van Hove M, Leng G. Trends in anticoagulant prescribing: A review of local policies in English primary care [Internet]. Vol. 20, BMC Health Services Research. BioMed Central Ltd.; 2020 [cited 2021 Feb 3]. Available from: https://doi.org/10.1186/s12913-020-5058-1

13. Coroners and Justice Act 2009. [Internet]. legislation.gov.uk. 2009 [cited 2020 Dec 15]. Available from: https://www.legislation.gov.uk/ukpga/2009/25/pdfs/ukpga_20090025_en.pdf

14. The Coroners (Investigations) Regulations 2013. [Internet]. legislation.gov.uk. 2013 [cited 2020 Dec 15]. Available from: https://www.legislation.gov.uk/uksi/2013/1629/pdfs/uksi_20131629_en.pdf

15. Ferner RE, Easton C, Cox AR. Deaths from Medicines: A Systematic Analysis of Coroners' Reports to Prevent Future Deaths. Drug Saf [Internet]. 2018;41(1):103–10. Available from: https://doi.org/10.1007/s40264-017-0588-0

16. Deaths from cardiovascular disease: A systematic analysis of coroners' reports to prevent future deaths in England and Wales [Internet]. OSF Registries. [cited 2021 Apr 15]. Available from: https://osf.io/rvw43

17. Prevention of Future Deaths [Internet]. Courts and Tribunals Judiciary. [cited 2021 Feb 3]. Available from: https://www.judiciary.uk/subject/prevention-of-future-deaths/

18. Preventable Deaths Tracker [Internet]. [cited 2021 Apr 15]. Available from: https://preventabledeathstracker.net/

19. GitHub - georgiarichards/georgiarichards.github.io [Internet]. [cited 2021 Apr 15]. Available from: https://github.com/georgiarichards/georgiarichards.github.io

20. DeVito NJ, Richards GC, Inglesby P. How we learnt to stop worrying and love web scraping. Nature [Internet]. 2020 Sep 1 [cited 2021 Feb 3];585(7826):621–2. Available from: https://doi.org/10.1038/d41586-020-02558-0

21. Kleinheksel AJ, Rockich-Winston N, Tawfik H, Wyatt TR. Demystifying content analysis. Am J Pharm Educ [Internet]. 2020 Jan 1 [cited 2021 Apr 28];84(1):127–37. Available from: https://doi.org/10.5688/ajpe7113

22. Deaths from cardiovascular disease: A systematic analysis of coroners' reports to prevent future deaths in England and Wales [Internet]. OSF. [cited 2021 Feb 3]. Available from: https://osf.io/qkfjp/

23. GitHub - georgiarichards/CVD_anticoags [Internet]. [cited 2021 Apr 17]. Available from: https://github.com/georgiarichards/CVD_anticoags

24. Ferner RE, Ahmad T, Babatunde Z, Cox AR. Preventing Future Deaths from Medicines: Responses to Coroners' Concerns in England and Wales. Drug Saf [Internet]. 2019 Mar 7 [cited 2021 Apr 17];42(3):445–51. Available from: https://doi.org/10.1007/s40264-018-0738-z

25. Leary A, Bushe D, Oldman C, Lawler J, Punshon G. A thematic analysis of the prevention of future deaths reports in healthcare from HM coroners in England and Wales 2016–2019. J Patient Saf Risk Manag [Internet]. 2021 Feb 3 [cited 2021 Apr 17];26(1):14–21. Available from: https://doi.org/10.1177/2516043521992651

26. Fox AW, Jacobson J. How well do Regulation 28 reports serve future public health and safety? Med Sci Law [Internet]. 2021 [cited 2021 Apr 13]; Available from: https://doi.org/10.1177/0025802420987431

27. Holden J, O'Donnell S, Brindley J, Miles L. Analysis of 1263 deaths in four general practices. Br J Gen Pract. 1998;48(432).

28. Mclean M, Roach J, Armitage R. Local variations in reporting deaths to the coroner in England and Wales: A postcode lottery? J Clin Pathol [Internet]. 2013 Nov [cited 2021 Apr 17];66(11):933–6. Available from: http://dx.doi.org/10.1136/jclinpath-2013-201640

29. Berry C, Heaton-Armstrong A. A review of the coroner system in England and Wales:

A commentary [Internet]. Vol. 5, Clinical Medicine, Journal of the Royal College of Physicians of London. Royal College of Physicians; 2005 [cited 2021 Apr 17]. p. 455–9. Available from: https://doi.org/10.7861/clinmedicine.5-5-455

30. Richards GC, Aronson JK, Heneghan C. Coroners' concerns to prevent harms: A series of coroners' case reports to serve patient safety and educate the public, clinicians and policy-makers [Internet]. BMJ Evidence-Based Medicine. BMJ Publishing Group; 2020 [cited 2021 Mar 11]. Available from: http://dx.doi.org/10.1136/bmjebm-2020-111567

31. Richards GC. Alcohol-based hand sanitisers: A warning to mitigate future poisonings and deaths. BMJ Evidence-Based Med [Internet]. 2020 Apr 1 [cited 2021 Apr 17];26(2):65–8. Available from: http://dx.doi.org/10.1136/bmjebm-2020-111568

32. Bilip MK, Richards GC. Emollients and smoking: a fire hazard that could be prevented to reduce future deaths. BMJ Evidence-Based Med [Internet]. 2021 Apr 9 [cited 2021 Apr 17];0:bmjebm-2020-111648. Available from: http://dx.doi.org/10.1136/bmjebm-2020-111648

33. Thomas ET, Richards GC. Diclofenac in adolescents: Diagnosing and treating gastrointestinal adverse drug reactions can prevent future deaths. BMJ Evidence-Based Med [Internet]. 2020 Feb 10 [cited 2021 Apr 17]; Available from: http://dx.doi.org/10.1136/bmjebm-2020-111640

34. Cox AR, Ferner R. Tramadol: Repeated prescriptions and repeated warnings [Internet]. BMJ Evidence-Based Medicine. BMJ Publishing Group; 2021 [cited 2021 Apr 17]. Available from: http://dx.doi.org/10.1136/bmjebm-2020-111661

35. Curtis HJ, MacKenna B, Walker AJ, Croker R, Mehrkar A, Morton CE, et al. OpenSAFELY: impact of national guidance on switching from warfarin to direct oral anticoagulants (DOACs) in early phase of COVID-19 pandemic in England. medRxiv [Internet]. 2020 Dec 4 [cited 2021 Jan 19];2020.12.03.20243535. Available from: https://doi.org/10.1101/2020.12.03.20243535

36. Single Technology Appraisal (STA): Andexanet alfa for reversing anticoagulation [ID1101] [Internet]. NICE. 2019 [cited 2021 Jan 19]. Available from: https://www.nice.org.uk/guidance/gid-ta10440/documents/scope-consultation-comments-and-responses

37. Andexanet alfa for reversing anticoagulation [ID1101] [Internet]. NICE. 2020 [cited

2021 Jan 19]. Available from: https://www.nice.org.uk/guidance/indevelopment/gid-ta10440

38. Andexanet alfa [Internet]. Specialist Pharmacy Service. 2020 [cited 2021 Jan 19]. Available from: https://www.sps.nhs.uk/medicines/andexanet-alfa/

39. 2019 surveillance of head injury: assessment and early management (NICE guideline CG176) [Internet]. NICE. 2019 [cited 2021 Jan 19]. Available from: https://www.nice.org.uk/guidance/cg176/resources/2019-surveillance-of-head-injury-assessment-and-early-management-nice-guideline-cg176-pdf-8944653877477

40. Head injury: assessment and early management [Internet]. NICE. 2019 [cited 2021 Jan 19]. Available from: https://www.nice.org.uk/guidance/cg176/chapter/1-Recommendations#investigating-clinically-important-brain-injuries

41. Puckett Y, Zhang K, Blasingame J, Lorenzana J, Parameswaran S, Brooks, MD, FACS SE, et al. Safest Time to Resume Oral Anticoagulation in Patients with Traumatic Brain Injury. Cureus [Internet]. 2018 Jul 3 [cited 2021 Jan 19];10(7). Available from: https://doi.org/10.7759/cureus.2920